In conclusion, GBM’s dismal prognosis is a consequence of its aggressive histopathological features compounded by a complex array of molecular mutations, including EGFR amplification/mutation, PTEN loss, TP53 mutation, TERT promoter mutations, and occasional IDH mutations. Here, IDH1 is linked to glioblastoma.